Estromineral Serena Plus and Symptomatic Menopause
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Oestrogen hormone deficiency in menopause leads to symptoms of which hot flushes, night sweats, insomnia and mood changes are the most frequent and, ultimately, worsen the quality of life. The gradual decline of oestrogen from peri-menopause results in altered function of many neurotransmitters, such as dopamine, melatonin and neuropeptides including beta-endorphins, which modulate the function of the hypothalamus and are involved in body thermoregulation.
In post-menopause, dopaminergic activity is significantly reduced and stimulus of the D2 receptors is effective in relieving hot flushes and in reducing the accompanying psychological symptoms.
The use of hormone replacement therapy, which is generally prescribed in the case of moderate or severe symptoms, is limited due to real contraindications or simply the woman's refusal to take the therapy, despite the presence of symptoms requiring its use.
A food supplement, named Estromineral (E), based on natural ingredients such as isoflavones, the absorption of which is increased by the presence of Lactobacillus sporogenes, and Vitamin D3 and calcium, strengthening bone mineralization, has been found to be effective at reducing vasomotor symptoms.
To potentiate the effect of E on the most frequent symptoms in menopause, it was considered rational to add the extracts of magnolia, active on psycho-affective symptoms, and chaste tree, acting on both hot flushes and psychological symptoms and a new food supplement was developed: Estromineral Serena Plus (ESP).
Estromineral Serena Plus is an association of isoflavones with added Lactobacillus, chaste tree and magnolia, active on menopausal vasomotor symptoms and on psycho-affective symptoms.
| Condition | Intervention |
|---|---|
|
Menopause |
Dietary Supplement: Estromineral Serena Plus Dietary Supplement: Estromineral |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Controlled Clinical Study on the Activity of the Combination of Isoflavones, Agnocastus and Magnolia Extract in Menopause |
- Kupperman index [ Time Frame: up to 12 weeks ] [ Designated as safety issue: No ]To calculate the Kupperman index, the symptoms were weighted as follows: hot flashes (4), insomnia (2), nervousness (2), and all other symptoms (night sweats, depressed mood (melancholy), dizziness, tiredness, joint and muscular pain, headache, and palpitations (1). The highest potential score is thus 51. The score of hot flashes was based on number of complaints per day: slight (more than 5), moderate (5-10), and severe (more than 10)
- Adverse events [ Time Frame: 4, 8 and 12 weeks ] [ Designated as safety issue: Yes ]Onset duration and severity of adverse events
| Estimated Enrollment: | 300 |
| Study Start Date: | November 2012 |
| Estimated Study Completion Date: | November 2013 |
| Estimated Primary Completion Date: | November 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Estromineral Serena Plus
Estromineral Serena Plus is an association of soy isoflavones, Lactobacillus sporogenes, magnolia, chaste tree, Vitamin D3, calcium and magnesium. 1 tablet oad for 12 weeks |
Dietary Supplement: Estromineral Serena Plus |
|
Active Comparator: Estromineral
Estromineral is an association of soy isoflavones, Lactobacillus sporogenes, Vitamin D3, and calcium. 1 tablet oad for 12 weeks |
Dietary Supplement: Estromineral |
Eligibility| Ages Eligible for Study: | 45 Years to 65 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- female menopausal age
- more than 5 hot flushes/day
- mood or sleep changes
Exclusion Criteria:
- hormone replacement therapy
Contacts and Locations| Italy | |
| Siena University | Not yet recruiting |
| Siena, Italy, 53100 | |
| Principal Investigator: Vincenzo De Leo, MD | |
| Principal Investigator: | Vincenzo De Leo, MD | Siena University |
More Information
No publications provided
| Responsible Party: | Rottapharm |
| ClinicalTrials.gov Identifier: | NCT01730989 History of Changes |
| Other Study ID Numbers: | ESP-CPR-0312 |
| Study First Received: | November 15, 2012 |
| Last Updated: | November 20, 2012 |
| Health Authority: | Italy: Ethics Committee |
Keywords provided by Rottapharm:
|
menopause Kupperman hot flushes |
isoflavones magnolia chaste tree |
ClinicalTrials.gov processed this record on May 16, 2013